Elevance Health Inc.
NYSE:ELVMedical - Healthcare Plans
-$3.45 today
- Market cap
- $86.60B
- Beta
- 0.68
- P/E (TTM)
- 16.3
- EPS (TTM)
- $23.78
- Dividend yield
- 1.77%
Volume 1.91M
Average 1.68M
ELV Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Elevance Health Inc.NYSE: ELV
Operating Expenses · Q3 FY2026 · quarter ended Sep 2026
Operating expenses dips below year-ago levels
Q3 FY2026 operating expenses of $5.86B fell 45.8% year over year, behind the +55.4% change in trailing-twelve-month operating expenses. Sequentially, it fell 86.4% from the prior quarter. Over 3 fiscal years it compounded at +10.7% a year.
Context
- Operating expenses amounted to 21.5% of revenue in FY2025, down 1.3 pp from a year earlier.
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -45.8% toward the trailing-twelve-month pace of +55.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 42.79B USD
- Year-over-year change
- +6.0%
- 4-year CAGR
- +12.2%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 42.79B | +6.0% |
| FY2024 | 2024-12-31 | 40.36B | +5.5% |
| FY2023 | 2023-12-31 | 38.27B | +21.5% |
| FY2022 | 2022-12-31 | 31.5B | +16.5% |
| FY2021 | 2021-12-31 | 27.05B | — |
Operating Expenses vs competitors
How ELV compares with its peers on the latest reported figures
- ELV's LTM Sep 2026 operating expenses of $66.32B is the 2nd highest of the 9 companies compared; the peer median is $18.94B.
- Its year-over-year change of +55.4% is the 3rd highest of 9, against a peer median of +16.2%.
- Operating expenses amounts to 32.9% of revenue for ELV, versus a peer median of 11.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $78.66B | +32.5% | +7.7% | 17.5% | |
| LTM Sep 2026 | $66.32B | +55.4% | +10.7% | 32.9% | |
| LTM Jun 2026 | $50.46B | +13.4% | -1.1% | 12.2% | |
| LTM Jun 2026 | $36.7B | +162.4% | +27.0% | 18.9% | |
| LTM Sep 2026 | $19.81B | +11.7% | +3.9% | 6.9% | |
| LTM Sep 2026 | $18.07B | +4.4% | +8.4% | 11.7% | |
| LTM Jun 2026 | $6.26B | +57.2% | -24.0% | 40.9% | |
| LTM Sep 2026 | $3.34B | +5.7% | +9.0% | 7.7% | |
| LTM Mar 2026 | $491.36M | +18.9% | +14.8% | 11.5% | |
| Peer median (excluding ELV) | $18.94B | +16.2% | +8.0% | 11.9% | |
Competitors are the stored peer set for ELV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 138.64B | 156.6B | 171.34B | 176.81B | 199.13B |
| Cost of Revenue | 102.65B | 116.64B | 124.33B | 127.57B | 148.22B |
| Gross Profit | 35.99B | 39.95B | 47.01B | 49.24B | 50.9B |
| Gross Margin | 26.0% | 25.5% | 27.4% | 27.9% | 25.6% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 27.05B | 31.5B | 38.27B | 40.36B | 42.79B |
| Depreciation & Amortization | 1.3B | 1.68B | 1.75B | 1.39B | 1.55B |
| EBITDA | 10.03B | 10.13B | 10.49B | 10.48B | 9.66B |
| EBITDA Margin | 7.2% | 6.5% | 6.1% | 5.9% | 4.9% |
| Operating Income | 8.95B | 8.45B | 8.75B | 8.89B | 8.11B |
| Operating Margin | 6.5% | 5.4% | 5.1% | 5.0% | 4.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 798M | 851M | 1.03B | 1.19B | 1.4B |
| Other Income / Expenses | (1.02B) | (851M) | (1.03B) | (984M) | (1.4B) |
| Income Before Tax | 7.93B | 7.6B | 7.72B | 7.9B | 6.71B |
| Pre-Tax Margin | 5.7% | 4.9% | 4.5% | 4.5% | 3.4% |
| Income Tax Expense | 1.83B | 1.71B | 1.72B | 1.93B | 1.05B |
| Net Income | 6.1B | 5.89B | 5.99B | 5.98B | 5.66B |
| Net Margin | 4.4% | 3.8% | 3.5% | 3.4% | 2.8% |
| EPS (Basic) | 25.25 | 24.56 | 25.38 | 25.81 | 25.18 |
| EPS (Diluted) | 24.73 | 24.28 | 25.22 | 25.68 | 25.12 |
| Weighted Avg Shares | 243.8M | 240M | 233.07M | 232.87M | 221.8M |
| Weighted Avg Shares (Diluted) | 246.8M | 242.8M | 237.4M | 232.9M | 221.8M |
Elevance Health Inc.
NYSE:ELV
Intrinsic Alpha fair value
Locked
Current Price
$400.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.